ALLERGY AND ASTHMA PROCEEDINGS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

RUNINGTITLE是必须的么？

44 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2021-12-27 桑晒麦拉

RUNNINGTITLE和TITLE的区别？

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2018-04-09 树梢上的皓月

"Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？

244 0

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2018-04-09 树梢上的皓月

"Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？

279 0

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2018-02-03 ms2877410299030514

主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。

102 0

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2018-02-03 G-01f74241

审稿速度:3.0 | 投稿命中率:75.0
经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。

290 0

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2017-11-28 二川溶溶

审稿速度:3.0 | 投稿命中率:50.0
经验分享：2016年为
2.614
2015年为
2.709
2014年为
3.061

270 0

[GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思，只接受约稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通，2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制，个人控制在10天左右，返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：2017年底上传了一份过敏性疾病的meta分析手稿，经过3个月返回第一轮修改意见，2位同行评审，提出意见不多属于可接受范围，没有修稿时间限制，个人控制在10天之内；之后只需要修改一个句子的表达以及调整图片，10+天得到最终的Decision Letter。虽然过程紧张，但主编和责任编辑都非常好沟通！小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2016年为 2.614 2015年为 2.709 2014年为 3.061 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以，感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]

2016-07-11 ms622773450447966

可以，感觉不错。

111 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务